These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion. Zhang ZG; Zhang L; Tsang W; Goussev A; Powers C; Ho KL; Morris D; Smyth SS; Coller BS; Chopp M Brain Res; 2001 Sep; 912(2):181-94. PubMed ID: 11532435 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of coronary artery reocclusion after thrombolysis with an RGD-containing peptide with no significant effect on bleeding time. Tschopp JF; Driscoll EM; Mu DX; Black SC; Pierschbacher MD; Lucchesi BR Coron Artery Dis; 1993 Sep; 4(9):809-17. PubMed ID: 8287215 [TBL] [Abstract][Full Text] [Related]
9. Angiographic evaluation of middle cerebral artery reperfusion caused by platelet glycoprotein IIb/IIIa receptor complex antagonist murine 7E3 F(ab')2 in a model of focal cerebral ischemia in rats. Yang Y; Li Q; Nakada MT; Yang T; Shuaib A J Neurosurg; 2001 Apr; 94(4):582-8. PubMed ID: 11302656 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke. Zhang L; Zhang ZG; Zhang R; Morris D; Lu M; Coller BS; Chopp M Circulation; 2003 Jun; 107(22):2837-43. PubMed ID: 12756151 [TBL] [Abstract][Full Text] [Related]
13. Human platelet activation is inhibited by the occupancy of glycoprotein IIb/IIIa receptor. Padoin E; Alexandre A; Cavallini L; Polverino de Laureto P; Rao GH; Doni MG Arch Biochem Biophys; 1996 Sep; 333(2):407-13. PubMed ID: 8809080 [TBL] [Abstract][Full Text] [Related]
14. The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke. Lapchak PA; Araujo DM; Song D; Zivin JA Stroke; 2002 Jan; 33(1):147-52. PubMed ID: 11779904 [TBL] [Abstract][Full Text] [Related]
15. Glycoprotein IIb/IIIa antagonist, murine 7E3 F(ab') 2, and tissue plasminogen activator in focal ischemia: evaluation of efficacy and risk of hemorrhage with combination therapy. Shuaib A; Yang Y; Nakada MT; Li Q; Yang T J Cereb Blood Flow Metab; 2002 Feb; 22(2):215-22. PubMed ID: 11823719 [TBL] [Abstract][Full Text] [Related]
16. The integrin alpha IIb beta 3 contains distinct and interacting binding sites for snake-venom RGD (Arg-Gly-Asp) proteins. Evidence that the receptor-binding characteristics of snake-venom RGD proteins are related to the amino acid environment flanking the sequence RGD. Rahman S; Lu X; Kakkar VV; Authi KS Biochem J; 1995 Nov; 312 ( Pt 1)(Pt 1):223-32. PubMed ID: 7492316 [TBL] [Abstract][Full Text] [Related]
18. Analysis of combined treatment of embolic stroke in rat with r-tPA and a GPIIb/IIIa inhibitor. Ding G; Jiang Q; Zhang L; Zhang ZG; Li L; Knight RA; Ewing JR; Wang Y; Chopp M J Cereb Blood Flow Metab; 2005 Jan; 25(1):87-97. PubMed ID: 15678115 [TBL] [Abstract][Full Text] [Related]
19. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Kleinschnitz C; Pozgajova M; Pham M; Bendszus M; Nieswandt B; Stoll G Circulation; 2007 May; 115(17):2323-30. PubMed ID: 17438148 [TBL] [Abstract][Full Text] [Related]